Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers.

Guerra SL, Maertens O, Kuzmickas R, De Raedt T, Adeyemi RO, Guild CJ, Guillemette S, Redig AJ, Chambers ES, Xu M, Tiv H, Santagata S, Jänne PA, Elledge SJ, Cichowski K.

Cancer Cell. 2020 Mar 19. pii: S1535-6108(20)30105-7. doi: 10.1016/j.ccell.2020.03.004. [Epub ahead of print]

PMID:
32243838
2.

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.

Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA.

JAMA Oncol. 2018 Nov 1;4(11):1527-1534. doi: 10.1001/jamaoncol.2018.2969.

3.

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.

Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne PA.

Clin Cancer Res. 2018 Dec 1;24(23):5963-5976. doi: 10.1158/1078-0432.CCR-18-0876. Epub 2018 Aug 2.

4.

Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation.

Cagney DN, Martin AM, Catalano PJ, Reitman ZJ, Mezochow GA, Lee EQ, Wen PY, Weiss SE, Brown PD, Ahluwalia MS, Arvold ND, Tanguturi SK, Haas-Kogan DA, Alexander BM, Redig AJ, Aizer AA.

Radiother Oncol. 2018 Mar;126(3):511-518. doi: 10.1016/j.radonc.2018.01.005. Epub 2018 Feb 3.

PMID:
29398153
5.

Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation.

Martin AM, Cagney DN, Catalano PJ, Alexander BM, Redig AJ, Schoenfeld JD, Aizer AA.

JAMA Oncol. 2018 Aug 1;4(8):1123-1124. doi: 10.1001/jamaoncol.2017.3993. No abstract available.

6.

Raising the bar: the future of EGFR inhibition in non-small lung cancer.

Redig AJ.

Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S58-S61. doi: 10.21037/tlcr.2017.10.09. No abstract available.

7.

Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.

Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, Janne PA, Shaw AT, McDonald Iii RE, Engelman JA, Stegmeier F, Schlabach MR, Hahn WC.

Elife. 2017 Oct 31;6. pii: e33173. doi: 10.7554/eLife.33173. No abstract available.

8.

Erratum: Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.

Zhang H, Brainson CF, Koyama S, Redig AJ, Chen T, Li S, Gupta M, Garcia-de-Alba C, Paschini M, Herter-Sprie GS, Lu G, Zhang X, Marsh BP, Tuminello SJ, Xu C, Chen Z, Wang X, Akbay EA, Zheng M, Palakurthi S, Sholl LM, Rustgi AK, Kwiatkowski DJ, Alan Diehl J, Bass AJ, Sharpless NE, Dranoff G, Hammerman PS, Ji H, Bardeesy N, Saur D, Watanabe H, Kim CF, Wong KK.

Nat Commun. 2017 Jun 9;8:15901. doi: 10.1038/ncomms15901.

9.

Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study.

Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, Wen PY, Dunn IF, Bi WL, Weiss SE, Haas-Kogan DA, Alexander BM, Aizer AA.

Neuro Oncol. 2017 Oct 19;19(11):1511-1521. doi: 10.1093/neuonc/nox077.

10.

Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.

Zhang H, Fillmore Brainson C, Koyama S, Redig AJ, Chen T, Li S, Gupta M, Garcia-de-Alba C, Paschini M, Herter-Sprie GS, Lu G, Zhang X, Marsh BP, Tuminello SJ, Xu C, Chen Z, Wang X, Akbay EA, Zheng M, Palakurthi S, Sholl LM, Rustgi AK, Kwiatkowski DJ, Diehl JA, Bass AJ, Sharpless NE, Dranoff G, Hammerman PS, Ji H, Bardeesy N, Saur D, Watanabe H, Kim CF, Wong KK.

Nat Commun. 2017 Apr 7;8:14922. doi: 10.1038/ncomms14922. Erratum in: Nat Commun. 2017 Jun 09;8:15901.

11.

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.

Kosaka T, Tanizaki J, Paranal RM, Endoh H, Lydon C, Capelletti M, Repellin CE, Choi J, Ogino A, Calles A, Ercan D, Redig AJ, Bahcall M, Oxnard GR, Eck MJ, Jänne PA.

Cancer Res. 2017 May 15;77(10):2712-2721. doi: 10.1158/0008-5472.CAN-16-3404. Epub 2017 Mar 31.

12.

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.

Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, Janne PA, Shaw AT, McDonald Iii RE, Engelman JA, Stegmeier F, Schlabach MR, Hahn WC.

Elife. 2017 Feb 1;6. pii: e18970. doi: 10.7554/eLife.18970. Erratum in: Elife. 2017 Oct 31;6:.

13.

Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial.

Redig AJ, Costa DB, Taibi M, Boucher D, Johnson BE, Jänne PA, Jackman DM.

JAMA Oncol. 2016 Sep 1;2(9):1240-2. doi: 10.1001/jamaoncol.2016.1304. No abstract available.

PMID:
27387964
14.

Targeting BET bromodomain proteins in solid tumors.

Sahai V, Redig AJ, Collier KA, Eckerdt FD, Munshi HG.

Oncotarget. 2016 Aug 16;7(33):53997-54009. doi: 10.18632/oncotarget.9804. Review.

15.

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.

Yanagita M, Redig AJ, Paweletz CP, Dahlberg SE, O'Connell A, Feeney N, Taibi M, Boucher D, Oxnard GR, Johnson BE, Costa DB, Jackman DM, Jänne PA.

Clin Cancer Res. 2016 Dec 15;22(24):6010-6020. Epub 2016 Jun 8.

16.

No Target Left Behind: Improving Therapeutic Options for ERBB2-Mutant Non-Small Cell Lung Cancer.

Redig AJ, Jänne PA.

J Thorac Oncol. 2016 Jun;11(6):784-6. doi: 10.1016/j.jtho.2016.04.009. No abstract available.

17.

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hammerman PS.

Nat Commun. 2016 Feb 17;7:10501. doi: 10.1038/ncomms10501.

18.

Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.

Redig AJ, Capelletti M, Dahlberg SE, Sholl LM, Mach S, Fontes C, Shi Y, Chalasani P, Jänne PA.

Clin Cancer Res. 2016 Jul 1;22(13):3148-56. doi: 10.1158/1078-0432.CCR-15-2377. Epub 2016 Feb 9.

19.

Basket trials and the evolution of clinical trial design in an era of genomic medicine.

Redig AJ, Jänne PA.

J Clin Oncol. 2015 Mar 20;33(9):975-7. doi: 10.1200/JCO.2014.59.8433. Epub 2015 Feb 9. No abstract available.

PMID:
25667288
20.

Interactive medical case. A chilly fever.

Redig AJ, Vaidya A, Price C, Katz JT, Maguire JH.

N Engl J Med. 2014 Oct 16;371(16):e24. doi: 10.1056/NEJMimc1315897. No abstract available.

PMID:
25317891
21.

Pathogenesis and clinical implications of HIV-related anemia in 2013.

Redig AJ, Berliner N.

Hematology Am Soc Hematol Educ Program. 2013;2013:377-81. doi: 10.1182/asheducation-2013.1.377. Review.

PMID:
24319207
22.

Breast cancer as a systemic disease: a view of metastasis.

Redig AJ, McAllister SS.

J Intern Med. 2013 Aug;274(2):113-26. doi: 10.1111/joim.12084. Review.

23.

Interactive medical case. A pain in the brain.

Redig AJ, Vaidya A, Bienfang DC, Milligan T.

N Engl J Med. 2013 Apr 11;368(15):e20. doi: 10.1056/NEJMimc1208949. No abstract available. Erratum in: N Engl J Med. 2013 Jun 27;368(26):2536. Dosage error in article text.

PMID:
23574142
24.

Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression.

Shields MA, Dangi-Garimella S, Redig AJ, Munshi HG.

Biochem J. 2012 Jan 15;441(2):541-52. doi: 10.1042/BJ20111240. Review.

PMID:
22187935
25.

A piece of my mind. The patient's patients.

Redig AJ.

JAMA. 2011 Jul 20;306(3):247-8. doi: 10.1001/jama.2011.934. No abstract available.

PMID:
21771979
26.

Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.

Altman JK, Sassano A, Kaur S, Glaser H, Kroczynska B, Redig AJ, Russo S, Barr S, Platanias LC.

Clin Cancer Res. 2011 Jul 1;17(13):4378-88. doi: 10.1158/1078-0432.CCR-10-2285. Epub 2011 Mar 17.

27.

The monsters of medicine: Political violence and the physician.

Redig AJ.

Pharos Alpha Omega Alpha Honor Med Soc. 2011 Winter;74(1):16-22. No abstract available.

PMID:
21384793
28.

Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL.

Redig AJ, Vakana E, Platanias LC.

Leuk Lymphoma. 2011 Feb;52 Suppl 1:45-53. doi: 10.3109/10428194.2010.546919. Review.

PMID:
21299459
29.

Incorporating fertility preservation into the care of young oncology patients.

Redig AJ, Brannigan R, Stryker SJ, Woodruff TK, Jeruss JS.

Cancer. 2011 Jan 1;117(1):4-10.

30.

Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy.

Redig AJ, Munshi HG.

Oncology (Williston Park). 2010 Aug;24(9):839-44. Review.

31.

Rho-ROCK-myosin signaling mediates membrane type 1 matrix metalloproteinase-induced cellular aggregation of keratinocytes.

Dangi-Garimella S, Redig AJ, Shields MA, Siddiqui MA, Munshi HG.

J Biol Chem. 2010 Sep 3;285(36):28363-72. doi: 10.1074/jbc.M110.146019. Epub 2010 Jul 6.

32.

Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy.

Redig AJ, Munshi HG.

Am J Med. 2010 Jan;123(1):87.e1-6. doi: 10.1016/j.amjmed.2009.06.022. Review.

33.

Adventures in (health-insurance-claim) wonderland.

Redig AJ.

Health Aff (Millwood). 2009 Sep-Oct;28(5):1515-20. doi: 10.1377/hlthaff.28.5.1515. No abstract available.

PMID:
19738271
34.

In search of sleep.

Redig AJ.

Acad Med. 2009 May;84(5):565. doi: 10.1097/01.ACM.0000351013.87233.e5. No abstract available.

PMID:
19704187
35.

Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses.

Joshi S, Kaur S, Redig AJ, Goldsborough K, David K, Ueda T, Watanabe-Fukunaga R, Baker DP, Fish EN, Fukunaga R, Platanias LC.

Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12097-102. doi: 10.1073/pnas.0900562106. Epub 2009 Jul 2.

36.

Activation of protein kinase C{eta} by type I interferons.

Redig AJ, Sassano A, Majchrzak-Kita B, Katsoulidis E, Liu H, Altman JK, Fish EN, Wickrema A, Platanias LC.

J Biol Chem. 2009 Apr 17;284(16):10301-14. doi: 10.1074/jbc.M807254200. Epub 2009 Feb 11.

37.

Protein kinase C signalling in leukemia.

Redig AJ, Platanias LC.

Leuk Lymphoma. 2008 Jul;49(7):1255-62. doi: 10.1080/10428190802007726. Review.

PMID:
18604714
38.

Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2.

Dolniak B, Katsoulidis E, Carayol N, Altman JK, Redig AJ, Tallman MS, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Platanias LC.

J Biol Chem. 2008 May 2;283(18):12034-42. doi: 10.1074/jbc.M708816200. Epub 2008 Feb 25.

39.

Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses.

Altman JK, Yoon P, Katsoulidis E, Kroczynska B, Sassano A, Redig AJ, Glaser H, Jordan A, Tallman MS, Hay N, Platanias LC.

J Biol Chem. 2008 Jan 25;283(4):1992-2001. Epub 2007 Nov 29.

40.

The protein kinase C (PKC) family of proteins in cytokine signaling in hematopoiesis.

Redig AJ, Platanias LC.

J Interferon Cytokine Res. 2007 Aug;27(8):623-36. Review.

PMID:
17784814
41.

Suppressive effects of statins on acute promyelocytic leukemia cells.

Sassano A, Katsoulidis E, Antico G, Altman JK, Redig AJ, Minucci S, Tallman MS, Platanias LC.

Cancer Res. 2007 May 1;67(9):4524-32.

42.

Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells.

Yoon P, Giafis N, Smith J, Mears H, Katsoulidis E, Sassano A, Altman J, Redig AJ, Tallman MS, Platanias LC.

Mol Cancer Ther. 2006 Nov;5(11):2815-23.

43.

A piece of my mind. Jigsaw.

Redig AJ.

JAMA. 2006 Jan 25;295(4):363-4. No abstract available.

PMID:
16434620
44.

Of men and microbes: physicians and the ethics of epidemics.

Redig AJ.

Virtual Mentor. 2006 Apr 1;8(4):194-6. doi: 10.1001/virtualmentor.2006.8.4.fred1-0604. No abstract available.

45.

Distributing drug samples in a free clinic: a personal or policy decision?

Redig AJ.

Virtual Mentor. 2006 Nov 1;8(11):729-34. doi: 10.1001/virtualmentor.2006.8.11.conl1-0611. No abstract available.

46.

Detection of rodent parvoviruses by use of fluorogenic nuclease polymerase chain reaction assays.

Redig AJ, Besselsen DG.

Comp Med. 2001 Aug;51(4):326-31. Erratum in: Comp Med. 2003 Apr;52(2):following table of contents.

PMID:
11924790

Supplemental Content

Loading ...
Support Center